1. Müller M (2006) Biological therapies: concepts and challenges. Wien Klin Wochenschr 118(17-18): 508–512
2. FDA (2004) Innovation or stagnation: challenge and opportunity on the critical path to new medical products.
www.fda.gov/oc/initiatives/criticalpath/whitepaper.html
3. IBM Business Consulting Services (1998) Pharma 2005 — an industrial revolution in R&D.
www-1.ibm.com/services/au/igs/pdf/gw510-9220-pharma-2005-industrial-revolution.pdf
4. Drews J (2000) Drug discovery: a historical perspective. Science 287: 1960–1964
5. Lazarou J, Pomeranz BH, Corey PN (1998) Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279: 1200–1205